Is durvalumab a drug targeting PD-1 or PD-L1?

Durvalumab/Durvalumab (durvalumab) is an immune checkpoint inhibitor that specifically targets PD-L1 (programmed death ligand 1) rather than PD-1 (programmed death protein 1). PD-L1 is an important immune regulatory molecule expressed on the surface of certain tumor cells. It binds to PD-1 on the surface of T cells and inhibits the activation and killing effects of T cells, allowing tumors to evade recognition and attack by the immune system. By targeting and blocking the binding of PD-L1 to PD-1 and CD80, durvalumab relieves the inhibitory effect of tumors on T cells and restores the body's immune surveillance and elimination capabilities against tumors.

Unlike other immune checkpoint inhibitors such as Nivolumab and Pembrolizumab, which mainly target PD-1, durvalumab targets PD-L1 molecules expressed by tumor cells and other immunosuppressive cells. This mechanism may bring about different immune activation profiles and adverse reaction characteristics. Studies have shown that durvalumab has lower immune-related toxicity in some cases because it does not interfere with the binding between PD-L2 and PD-1 and retains part of the immune self-stabilizing function.

Clinically, durvalumab is widely used to treat unresectable stage III non-small cell lung cancer (NSCLC), extensive stage small cell lung cancer (ES-SCLC), locally advanced or metastatic biliary tract cancer, unresectable hepatocellular carcinoma (HCC) and other cancers. As an immunotherapy drug, it does not rely on gene mutation targets in traditional chemotherapy or targeted therapy, but activates a broad-spectrum anti-tumor immune response. Its efficacy is closely related to the expression level of PD-L1 and the tumor immune microenvironment.

Overall, durvalumab represents an important progress in tumor immunotherapy. By precisely blockingPD-L1's key role in tumor immune escape, it provides new treatment options for a variety of advanced solid tumors and promotes the rapid development of immune combination therapy strategies.

Reference materials:https://www.imfinzi.com/